AI Engines For more Details: Perplexity Kagi Labs You
Nutritional Value: Oyster mushrooms are low in calories and fat but rich in protein, fiber, vitamins (such as B vitamins, vitamin D, and vitamin C), minerals (such as potassium, phosphorus, and iron), and antioxidants. Including oyster mushrooms in your diet can contribute to overall nutrient intake and support various bodily functions.
Immune Support: Oyster mushrooms contain bioactive compounds like beta-glucans, polysaccharides, and lectins, which have immunomodulatory properties. These compounds may help enhance immune function by stimulating the activity of immune cells, promoting the production of cytokines, and increasing the body's defense against infections and diseases.
Antioxidant Activity: Oyster mushrooms are rich in antioxidants, including phenolic compounds and ergothioneine, which help neutralize harmful free radicals and reduce oxidative stress in the body. Antioxidants protect cells from damage, inflammation, and premature aging, and they may lower the risk of chronic diseases such as heart disease, cancer, and neurodegenerative disorders.
Anti-Inflammatory Effects: Compounds found in oyster mushrooms, such as ergothioneine, inhibit inflammatory pathways and cytokine production, leading to potential anti-inflammatory effects. Consuming oyster mushrooms may help alleviate inflammation-related conditions like arthritis, asthma, and inflammatory bowel disease.
Cholesterol Regulation: Oyster mushrooms contain lovastatin, a natural compound that inhibits cholesterol synthesis in the body. Regular consumption of oyster mushrooms may help lower LDL (bad) cholesterol levels and reduce the risk of cardiovascular disease.
Blood Sugar Control: Some studies suggest that oyster mushrooms may have hypoglycemic effects and help improve insulin sensitivity, making them beneficial for individuals with diabetes or those at risk of developing diabetes. The soluble fiber and polysaccharides in oyster mushrooms may slow down the absorption of glucose in the bloodstream and stabilize blood sugar levels.
Digestive Health: Oyster mushrooms are a good source of dietary fiber, which promotes digestive health by regulating bowel movements, preventing constipation, and supporting the growth of beneficial gut bacteria. Fiber also helps maintain a healthy weight and may reduce the risk of colon cancer.
Antimicrobial Properties: Oyster mushrooms exhibit antimicrobial activity against various bacteria, viruses, and fungi, including common pathogens like Escherichia coli and Staphylococcus aureus. Including oyster mushrooms in your diet may help boost your body's natural defenses against microbial infections.
Cognitive Function: Some research suggests that oyster mushrooms contain compounds that may have neuroprotective effects and support cognitive function. These compounds may help prevent age-related cognitive decline, improve memory, and enhance overall brain health.
Skin Health: The antioxidants and vitamin D found in oyster mushrooms may contribute to skin health by protecting against UV damage, promoting collagen synthesis, and reducing signs of aging, such as wrinkles and age spots.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.9 | 0.9 | |
| ADHD | 0.3 | 1.9 | -5.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.6 | -1 |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.7 | |
| Allergies | 1.2 | 1.6 | -0.33 |
| Allergy to milk products | 1.1 | 1.3 | -0.18 |
| Alopecia (Hair Loss) | 1.2 | -1.2 | |
| Alzheimer's disease | 4.1 | 1.8 | 1.28 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 1.3 | 0.23 |
| Ankylosing spondylitis | 1.7 | 1.8 | -0.06 |
| Anorexia Nervosa | 1.9 | 1.9 | |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | 0 |
| Asthma | 1.3 | 1.1 | 0.18 |
| Atherosclerosis | 0.8 | 0.6 | 0.33 |
| Atrial fibrillation | 0.6 | 2.2 | -2.67 |
| Autism | 4.3 | 3 | 0.43 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 1 | 1 | |
| Bipolar Disorder | 1.6 | 1.6 | |
| Brain Trauma | 0.8 | 0.9 | -0.13 |
| Carcinoma | 1.7 | 1.2 | 0.42 |
| Celiac Disease | 2.2 | 0.8 | 1.75 |
| Cerebral Palsy | 1.2 | 0.6 | 1 |
| Chronic Fatigue Syndrome | 1.3 | 0.6 | 1.17 |
| Chronic Kidney Disease | 1.9 | 1.9 | |
| Chronic Lyme | 0.8 | 0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.3 | 1 |
| Chronic Urticaria (Hives) | 0.7 | 0.7 | |
| Coagulation / Micro clot triggering bacteria | 2.4 | 2.4 | |
| Colorectal Cancer | 2.3 | 1.8 | 0.28 |
| Constipation | 2.5 | 0.3 | 7.33 |
| Coronary artery disease | 0.9 | 0.3 | 2 |
| COVID-19 | 4.7 | 2.4 | 0.96 |
| Crohn's Disease | 4 | 2.2 | 0.82 |
| cystic fibrosis | 1.9 | 1.9 | |
| deep vein thrombosis | 1.8 | 1.8 | |
| Depression | 3.8 | 4.5 | -0.18 |
| Dermatomyositis | 0.6 | 0.6 | |
| Eczema | 2.1 | 2.1 | |
| Endometriosis | 1.4 | 1.2 | 0.17 |
| Epilepsy | 2.5 | 1.5 | 0.67 |
| erectile dysfunction | 0.3 | -0.3 | |
| Fibromyalgia | 1.1 | 1.6 | -0.45 |
| Functional constipation / chronic idiopathic constipation | 2.6 | 1.6 | 0.63 |
| gallstone disease (gsd) | 1.7 | 0.6 | 1.83 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.4 | |
| Generalized anxiety disorder | 2 | 0.6 | 2.33 |
| Glioblastoma | 0.3 | 0.3 | |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 1.5 | 1.1 | 0.36 |
| Hashimoto's thyroiditis | 0.6 | 2.1 | -2.5 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 1.2 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 2.2 | 0.3 | 6.33 |
| Hyperlipidemia (High Blood Fats) | 0.6 | -0.6 | |
| hypersomnia | 0.6 | 0.6 | |
| hypertension (High Blood Pressure | 3.3 | 1.5 | 1.2 |
| Hypothyroidism | 1.5 | 1.5 | |
| IgA nephropathy (IgAN) | 0.8 | 0.3 | 1.67 |
| Inflammatory Bowel Disease | 3.4 | 0.6 | 4.67 |
| Insomnia | 0.6 | 0.6 | 0 |
| Intelligence | 0.3 | -0.3 | |
| Intracranial aneurysms | 0.6 | -0.6 | |
| Irritable Bowel Syndrome | 2.9 | 1.8 | 0.61 |
| Liver Cirrhosis | 2 | 2.1 | -0.05 |
| Long COVID | 4 | 2.3 | 0.74 |
| Low bone mineral density | 0.9 | 0.9 | |
| Lung Cancer | 1.9 | 1.9 | |
| ME/CFS with IBS | 1 | 1 | |
| ME/CFS without IBS | 0.6 | 0.6 | |
| Menopause | 0.2 | 0.4 | -1 |
| Metabolic Syndrome | 5 | 3.2 | 0.56 |
| Mood Disorders | 4 | 4.8 | -0.2 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 0.9 | 1.4 | -0.56 |
| Multiple system atrophy (MSA) | 1.4 | 0.2 | 6 |
| myasthenia gravis | 0.3 | -0.3 | |
| Neuropathy (all types) | 1.4 | -1.4 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 0.9 | 3 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
| Obesity | 3 | 3.1 | -0.03 |
| obsessive-compulsive disorder | 2.6 | 0.2 | 12 |
| Osteoarthritis | 0.7 | 0.3 | 1.33 |
| Osteoporosis | 1.9 | 1.9 | |
| Parkinson's Disease | 2.7 | 1.6 | 0.69 |
| Polycystic ovary syndrome | 2.5 | 1.2 | 1.08 |
| Postural orthostatic tachycardia syndrome | 0.8 | 0.8 | |
| Premenstrual dysphoric disorder | 1.2 | -1.2 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Psoriasis | 0.8 | 1.2 | -0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.3 | 2.7 | 0.22 |
| Rosacea | 0.6 | 0.6 | 0 |
| Schizophrenia | 2.1 | 1.6 | 0.31 |
| scoliosis | 0.3 | -0.3 | |
| sensorineural hearing loss | 0.3 | 0.3 | |
| Sjögren syndrome | 2.7 | 0.6 | 3.5 |
| Sleep Apnea | 2 | 1.2 | 0.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 2.4 | 1.5 | 0.6 |
| Systemic Lupus Erythematosus | 3.4 | 0.6 | 4.67 |
| Tic Disorder | 0.8 | 0.8 | |
| Type 1 Diabetes | 1.7 | 0.9 | 0.89 |
| Type 2 Diabetes | 3.6 | 2.5 | 0.44 |
| Ulcerative colitis | 3.3 | 1.5 | 1.2 |
| Unhealthy Ageing | 1.4 | 1.4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.